Sanofi (SNY) Reports Regulatory Win, Barclays Downgrades to ‘Equal Weight' with EUR 85 PT [Yahoo! Finance]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: Yahoo! Finance
On January 6, 2026, Barclays downgraded Sanofi (NASDAQ:SNY) from ‘Overweight' to ‘Equal Weight', while setting an EUR 85 price target. The firm's update reflects its more cautious long-term outlook on the company despite the strong operational outlook and an undemanding valuation. Barclays recommends caution due to concerns around limited late-stage pipeline depth and the approaching loss of exclusivity for Dupixent. The bank sees the loss as a growing overhang on the company's medium- to long-term growth profile despite solid near-term execution expectations. Meanwhile, Sanofi (NASDAQ:SNY) reported a regulatory win on January 5, 2025, when the FDA accepted the supplemental BLA for Tzield for priority review to further its use in children as young as one year old with stage 2 type 1 diabetes. The filing, supported by interim Phase 4 PETITE-T1D data, reflects the company's ability to extend lifecycle value from its existing assets. The FDA decision is expected to come out by April 2
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- Sanofi (NASDAQ:SNY) had its "buy" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.MarketBeat
- Sanofi (NASDAQ:SNY) was downgraded by analysts at UBS Group AG from a "buy" rating to a "neutral" rating.MarketBeat
- JPM26: Leo Pharma's growth strategy puts a spotlight on rare dermatology diseases [Yahoo! Finance]Yahoo! Finance
- State Street's crypto push, FDA delays review of Eli Lilly GLP-1 [Yahoo! Finance Canada]Yahoo! Finance Canada
- Why Sanofi May Need To Top $2.4 Billion For Ocular Therapeutix [Seeking Alpha]Seeking Alpha
SNY
Sec Filings
- 1/16/26 - Form 6-K
- 1/9/26 - Form 6-K
- 12/29/25 - Form 6-K
- SNY's page on the SEC website